10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
4D Molecular Therapeutics Inc. (FDMT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 5,049,779 | $47,013,442 | -11% | 0.5% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,879,289 | $26,806,181 | -38% | 0.85% |
| 3. | Armistice Capital Steven Boyd | 2,000,000 | $18,620,000 | +4% | 0.33% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,605,156 | $14,944,002 | +30% | 0.02% |
| 5. | Trails Edge Capital Partners Ortav (Tavi) Yehudai | 1,302,917 | $12,130,157 | 2.78% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 850,000 | $13,600,000.00 | 4,787,914 | 2023-05-09 | Filing | |
| $23.00 | 1,100,000 | $25,300,000.00 | 3,937,914 | 2020-12-15 | Filing | |
| $23.00 | 100,000 | $2,300,000.00 | 100,000 | 2020-12-15 | Filing | |
| $23.00 | 4,347 | $99,981.00 | 4,347 | 2020-12-15 | Filing | |
| $23.00 | 425,000 | $9,775,000.00 | 1,060,880 | 2020-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.00 | 6,566 | $91,924.00 | 8,617 | 2026-06-30 | Filing | |
| $12.00 | 9,810 | $117,720.00 | 8,617 | 2026-06-23 | Filing | |
| $10.47 | 114,746 | $1,200,851.31 | 942,485 | 2026-06-22 | Filing | |
| $10.02 | 1,922 | $19,257.86 | 1,057,231 | 2026-06-01 | Filing | |
| $8.61 | 80 | $688.80 | 47,055 | 2026-03-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 83,333 | $1,108,329 | 0% | |
| 2. | 1,334 | $17,742 | 0% | |
| 3. | 728 | $9,682 | 0% | |
| 4. | 740 | $9,634 | 0.01% |
News See All
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the top gene therapy stocks to buy according to hedge funds. 4D Molecular Therapeutics, Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)
TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D Molecular Therapeutics, Inc.
13 Best Get Rich Fast Stocks to Buy Right Now
In today's fast-paced world, everyone is prioritising investments that have both high and relatively quick returns.
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is one of the hot stocks to buy with huge upside potential.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Jim Cramer Answered Questions About These 10 Stocks Recently
On Tuesday’s episode of Mad Money, host Jim Cramer, with the help of commodity broker and futures analyst Carley Garner’s interpretation of charts, raised caution over potential warning signs developing...
Hedge Fund Resource Center